Monoclonal antibodies against human platelet membrane glycoprotein IIIa and collagen-induced platelet activation.
نویسندگان
چکیده
منابع مشابه
The platelet membrane glycoprotein IIb-IIIa complex.
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information abo...
متن کاملMonoclonal Antibodies Against Porcine Platelet Membrane Glycoproteins lb and
We prepared murine monoclonal antibodies to porcine platelet membrane glycoprotein (GP) lb and GP llb/Illa for further study of the porcine hemostatic mechanism. One monoclonal antibody, designated PP3-4C. blocked Ristocetin-induced platelet agglutination and caused 80% inhibition of Ristocetin-induced ‘25l-von Willebrand factor (vWF) binding to porcine platelets at a concentration of 1 2 gsg l...
متن کاملRole of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins
Treatment of platelets with thrombin was shown previously to induce rapid changes in tyrosine phosphorylation of several platelet proteins. In this report, we demonstrate that a variety of agonists which induce platelet aggregation also stimulate tyrosine phosphorylation of three proteins with apparent molecular masses of 84, 95, and 97 kD. Since platelet aggregation requires the agonist-induce...
متن کاملPlatelet Glycoprotein IIb/IIIa Inhibitors
Glycoprotein IIb/IIIa (GPIIb-IIIa) complexes (integrin aIIbb3) mediate platelet aggregation by binding fibrinogen or von Willebrand factor (vWF), protein cofactors that form bridges between adjacent platelets. The cross-linked adhesive proteins assemble platelets into the aggregate. Agents that block the function of the GPIIb-IIIa complex of platelets constitute a powerful new generation of ant...
متن کاملPlatelet glycoprotein IIb/IIIa inhibitors.
To the Editor: Platelet glycoprotein (GP) IIb/IIIa antagonists only prompt an overall 8.5% relative reduction in 30-day deaths or myocardial infarction in acute coronary syndromes (ACS),1 and Quinn et al1 suggested that this limited benefit may be due to factors such as antagonist-induced platelet activation. I suggest that limited benefits of GP IIb/IIIa inhibition are due basically to limited...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chemical and Pharmaceutical Bulletin
سال: 1989
ISSN: 0009-2363,1347-5223
DOI: 10.1248/cpb.37.397